Gabe Ortiz, MD, PhD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address1001 Potrero Avenue, #H5834
San Francisco CA 94110
Phone628-206-2355
PronounsHe/Him/His
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    Yale Univeristy, New Haven, CTMS, BS1996Molecular Biophysics and Biochemistry
    Tri-Institutional MD, PhD Program, New York, NYMD, PhD2004Medicine and Human Immunology
    UCSF, San Francisco, CAResidency2007Internal Medicine
    UCSF, San Francisco, CAChief Residency2008Internal Medicine
    UCSF, San Francisco, CAFellowship2012Infectious Diseases
    University of California, San Francisco, CA2018Diversity, Equity, and Inclusion Champion Training

    Collapse Overview 
    Collapse overview
    Gabriel Ortiz (aka: Gabe), MD, PhD, is a Clinical Professor at UCSF and a dedicated hospitalist at Zuckerberg San Francisco General (ZSFG). In his role as the Chief Medical Officer at ZSFG, Dr. Ortiz is committed to quality improvement initiatives aimed at enhancing the care provided to the diverse and vulnerable communities served by the hospital. He is a strong advocate for the implementation of Toyota’s LEAN production and LEAN daily management systems, leveraging these methodologies to drive transformative changes within healthcare systems (see links below for more information).

    Dr. Ortiz’s primary focus is on ensuring that the care delivered at ZSFG is of the highest quality, safe, and equitable for all patients. His leadership and expertise in healthcare system optimization are pivotal in fostering an environment where patient-centered care thrives and staff are supported. Through his efforts, Dr. Ortiz makes significant strides in advancing healthcare excellence and equity.

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Featured Content 
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Characterizing patients hospitalized without an acute care indication: A retrospective cohort study. J Hosp Med. 2023 04; 18(4):294-301. Rosenthal MA, Ranji SR, Kanzaria HK, Ortiz GM, Chase J, Chodos AH, Nguyen OK, Rodriguez EG, Makam AN. PMID: 36757173.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. The Evolution of a Hospital-Based Covid-19 Vaccination Program for Inpatients. NEJM Catalyst. 2022; 3(2):1-16. Dana Freiser, BS, BA, RN, Merjo Roca, BA, RN, Tony Chung, PharmD, Tanvi Bhakta, MSN, RN, CNL, Lisa G. Winston, MD, Gabriel M. Ortiz, MD, PhD. View Publication.
    3. Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01. EClinicalMedicine. 2021 Oct; 40:101099. Weiner J, Suwalski P, Holtgrewe M, Rakitko A, Thibeault C, Müller M, Patriki D, Quedenau C, Krüger U, Ilinsky V, Popov I, Balnis J, Jaitovich A, Helbig ET, Lippert LJ, Stubbemann P, Real LM, Macías J, Pineda JA, Fernandez-Fuertes M, Wang X, Karadeniz Z, Saccomanno J, Doehn JM, Hübner RH, Hinzmann B, Salvo M, Blueher A, Siemann S, Jurisic S, Beer JH, Rutishauser J, Wiggli B, Schmid H, Danninger K, Binder R, Corman VM, Mühlemann B, Arjun Arkal R, Fragiadakis GK, Mick E, Comet C, Calfee CS, Erle DJ, Hendrickson CM, Kangelaris KN, Krummel MF, Woodruff PG, Langelier CR, Venkataramani U, García F, Zyla J, Drosten C, Alice B, Jones TC, Suttorp N, Witzenrath M, Hippenstiel S, Zemojtel T, Skurk C, Poller W, Borodina T, Pa-Covid SG, Ripke S, Sander LE, Beule D, Landmesser U, Guettouche T, Kurth F, Heidecker B. PMID: 34490415; PMCID: PMC8410317.
      View in: PubMed   Mentions: 52  
    4. Tracheal aspirate RNA sequencing identifies distinct immunological features of COVID-19 ARDS. Nat Commun. 2021 08 26; 12(1):5152. Sarma A, Christenson SA, Byrne A, Mick E, Pisco AO, DeVoe C, Deiss T, Ghale R, Zha BS, Tsitsiklis A, Jauregui A, Moazed F, Detweiler AM, Spottiswoode N, Sinha P, Neff N, Tan M, Serpa PH, Willmore A, Ansel KM, Wilson JG, Leligdowicz A, Siegel ER, Sirota M, DeRisi JL, Matthay MA, COMET Consortium, Hendrickson CM, Kangelaris KN, Krummel MF, Woodruff PG, Erle DJ, Calfee CS, Langelier CR. PMID: 34446707; PMCID: PMC8390461.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    5. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci Transl Med. 2021 Sep 22; 13(612):eabh2624. van der Wijst MGP, Vazquez SE, Hartoularos GC, Bastard P, Grant T, Bueno R, Lee DS, Greenland JR, Sun Y, Perez R, Ogorodnikov A, Ward A, Mann SA, Lynch KL, Yun C, Havlir DV, Chamie G, Marquez C, Greenhouse B, Lionakis MS, Norris PJ, Dumont LJ, Kelly K, Zhang P, Zhang Q, Gervais A, Le Voyer T, Whatley A, Si Y, Byrne A, Combes AJ, Rao AA, Song YS, Fragiadakis GK, Kangelaris K, Calfee CS, Erle DJ, Hendrickson C, Krummel MF, Woodruff PG, Langelier CR, Casanova JL, Derisi JL, Anderson MS, Ye CJ, UCSF COMET consortium. PMID: 34429372; PMCID: PMC8601717.
      View in: PubMed   Mentions: 116     Fields:    Translation:Humans
    6. Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19: Anti-IFN antibodies in critical COVID-19 correlate with poor ISG response and upregulation of LAIR1 surface protein in PBMCs. bioRxiv. 2021 Mar 10. van der Wijst MGP, Vazquez SE, Hartoularos GC, Bastard P, Grant T, Bueno R, Lee DS, Greenland JR, Sun Y, Perez R, Ogorodnikov A, Ward A, Mann SA, Lynch KL, Yun C, Havlir DV, Chamie G, Marquez C, Greenhouse B, Lionakis MS, Norris PJ, Dumont LJ, Kelly K, Zhang P, Zhang Q, Gervais A, Le Voyer T, Whatley A, Si Y, Byrne A, Combes AJ, Rao AA, Song YS, UCSF COMET consortium, Fragiadakis GK, Kangelaris K, Calfee CS, Erle DJ, Hendrickson C, Krummel MF, Woodruff PG, Langelier CR, Casanova JL, Derisi JL, Anderson MS, Ye CJ. PMID: 33758859; PMCID: PMC7987018.
      View in: PubMed   Mentions: 1  
    7. Acute Care for Patients Who Are Incarcerated: A Review. JAMA Intern Med. 2019 Nov 01; 179(11):1561-1567. Haber LA, Erickson HP, Ranji SR, Ortiz GM, Pratt LA. PMID: 31524937.
      View in: PubMed   Mentions: 20     Fields:    
    8. By the Light of Day: Quality, Safety, and Education During the Overnight Admission Handoff. Cureus. 2019 Apr 23; 11(4):e4529. Devendra GP, Ortiz GM, Haber LA. PMID: 31263637; PMCID: PMC6592463.
      View in: PubMed   Mentions: 2  
    9. Acute Clinical Care for Transgender Patients: A Review. JAMA Intern Med. 2018 11 01; 178(11):1535-1543. Rosendale N, Goldman S, Ortiz GM, Haber LA. PMID: 30178031.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    10. Unusual Radiographic Presentation of Pneumocystis Pneumonia in a Patient with AIDS. Case Rep Infect Dis. 2017; 2017:3183525. Block BL, Mehta T, Ortiz GM, Ferris SP, Vu TH, Huang L, Cattamanchi A. PMID: 29362681; PMCID: PMC5738569.
      View in: PubMed   Mentions: 7  
    11. Clearing the air: inpatient providers' knowledge, perspectives, and experience with electronic cigarettes. J Hosp Med. 2014 Dec; 9(12):805-7. Haber LA, Ortiz GM. PMID: 25352497.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    12. Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4(+) T cell recovery after the initiation of antiretroviral therapy for HIV disease. AIDS Res Ther. 2014; 11:27. Seu L, Ortiz GM, Burt TD, Deeks SG, Martin JN, McCune JM. PMID: 25180041; PMCID: PMC4150425.
      View in: PubMed   Mentions: 2     Fields:    
    13. Higher CD27+CD8+ T cells percentages during suppressive antiretroviral therapy predict greater subsequent CD4+ T cell recovery in treated HIV infection. PLoS One. 2013; 8(12):e84091. Seu L, Ortiz GM, Epling L, Sinclair E, Swainson LA, Bajpai UD, Huang Y, Deeks SG, Hunt PW, Martin JN, McCune JM. PMID: 24391889; PMCID: PMC3877182.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    14. Morphine produces immunosuppressive effects in nonhuman primates at the proteomic and cellular levels. Mol Cell Proteomics. 2012 Sep; 11(9):605-18. Brown JN, Ortiz GM, Angel TE, Jacobs JM, Gritsenko M, Chan EY, Purdy DE, Murnane RD, Larsen K, Palermo RE, Shukla AK, Clauss TR, Katze MG, McCune JM, Smith RD. PMID: 22580588; PMCID: PMC3434775.
      View in: PubMed   Mentions: 23     Fields:    Translation:AnimalsCells
    15. Detection of T lymphocytes specific for human endogenous retrovirus K (HERV-K) in patients with seminoma. AIDS Res Hum Retroviruses. 2006 Jan; 22(1):52-6. Rakoff-Nahoum S, Kuebler PJ, Heymann JJ, E Sheehy M, Ortiz GM, S Ogg G, Barbour JD, Lenz J, Steinfeld AD, Nixon DF. PMID: 16438646.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    16. Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3. J Acquir Immune Defic Syndr. 2004 Jul 01; 36(3):791-9. Plana M, Garcia F, Oxenius A, Ortiz GM, Lopez A, Cruceta A, Mestre G, Fumero E, Fagard C, Sambeat MA, Segura F, Miró JM, Arnedo M, Lopalcos L, Pumarola T, Hirschel B, Phillips RE, Nixon DF, Gallart T, Gatell JM. PMID: 15213562.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    17. Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. J Acquir Immune Defic Syndr. 2003 Dec 15; 34(5):475-81. Alexander TH, Ortiz GM, Wellons MF, Allen A, Grace EJ, Schweighardt B, Brancato J, Sandberg JK, Furlan SN, Miralles GD, Nixon DF, Bartlett JA. PMID: 14657757.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    18. Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. J Virol. 2003 Jun; 77(12):6743-52. Karlsson AC, Deeks SG, Barbour JD, Heiken BD, Younger SR, Hoh R, Lane M, Sällberg M, Ortiz GM, Demarest JF, Liegler T, Grant RM, Martin JN, Nixon DF. PMID: 12767994; PMCID: PMC156163.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    19. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. AIDS. 2003 Jan 03; 17(1):43-51. García F, Plana M, Arnedo M, Ortiz GM, Miró JM, Lopalco L, Lori F, Pumarola T, Gallart T, Gatell JM. PMID: 12478068.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    20. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS. 2002 Nov 22; 16(17):2342-4. Schweighardt B, Ortiz GM, Grant RM, Wellons M, Miralles GD, Kostrikis LG, Bartlett JA, Nixon DF. PMID: 12441810.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    21. Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection. J Virol. 2002 Jan; 76(1):411-5. Ortiz GM, Hu J, Goldwitz JA, Chandwani R, Larsson M, Bhardwaj N, Bonhoeffer S, Ramratnam B, Zhang L, Markowitz MM, Nixon DF. PMID: 11739706; PMCID: PMC135693.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    22. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A. 2001 Nov 06; 98(23):13288-93. Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, Van Loon K, Bonhoeffer S, Miralles GD, Montefiori D, Bartlett JA, Nixon DF. PMID: 11687611; PMCID: PMC60863.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCellsCTClinical Trials
    23. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS. 2001 Jun 15; 15(9):F29-40. García F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C, Cruceta A, Arnedo M, Gil C, Pantaleo G, Pumarola T, Gallart T, Nixon DF, Miró JM, Gatell JM. PMID: 11416735.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCellsCTClinical Trials
    24. Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection. AIDS. 2000 Oct 20; 14(15):2313-22. Bonhoeffer S, Rembiszewski M, Ortiz GM, Nixon DF. PMID: 11089619.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    25. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis. 2000 Sep; 182(3):766-75. Papasavvas E, Ortiz GM, Gross R, Sun J, Moore EC, Heymann JJ, Moonis M, Sandberg JK, Drohan LA, Gallagher B, Shull J, Nixon DF, Kostman JR, Montaner LJ. PMID: 10950770.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCellsCTClinical Trials
    26. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. J Infect Dis. 2000 Apr; 181(4):1249-63. Binley JM, Schiller DS, Ortiz GM, Hurley A, Nixon DF, Markowitz MM, Moore JP. PMID: 10762561.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    27. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest. 1999 Sep; 104(6):R13-8. Ortiz GM, Nixon DF, Trkola A, Binley J, Jin X, Bonhoeffer S, Kuebler PJ, Donahoe SM, Demoitie MA, Kakimoto WM, Ketas T, Clas B, Heymann JJ, Zhang L, Cao Y, Hurley A, Moore JP, Ho DD, Markowitz M. PMID: 10491418; PMCID: PMC408442.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    28. Cell-free transfer of cholesterol from lysosomes to phospholipid vesicles. J Lipid Res. 1996 Jan; 37(1):54-66. Johnson WJ. PMID: 8820102.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    29. Digitoxin metabolism by rat liver microsomes. Biochem Pharmacol. 1975 Sep 01; 24(17):1639-41. Schmoldt A, Benthe HF, Haberland G. PMID: 10.
      View in: PubMed   Mentions: 56     Fields:    Translation:AnimalsCells
    30. [Biochemical studies on camomile components/III. In vitro studies about the antipeptic activity of (--)-alpha-bisabolol (author's transl)]. Arzneimittelforschung. 1975 Sep; 25(9):1352-4. Isaac O, Thiemer K. PMID: 21.
      View in: PubMed   Mentions: 5     Fields:    Translation:Animals
    31. The ophthalmologist's office: planning and practice. Patient traffic flow and use of paramedical personnel. Int Ophthalmol Clin. 1975; 15(2):133-9. Byron HM. PMID: 340.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    32. “Acinetobacter in military personnel.” Case vignette as part of www.antimicrobe.org. Gabriel M. Ortiz and David Graham. . View Publication.
    Gabe's Networks
    Concepts (144)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (76)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-15-g9ae42700 on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.